Inbrain Neuroelectronics has secured a loan from the European Investment Bank (EIB) for a total of 20 million euros. The biotech, member of CataloniaBio & HealthTech, led by Carolina Aguilar, will be able to advance the clinical development of its neurology R&D programmes for diseases such as Parkinson's disease, epilepsy and speech disorders.

The loan also gives the company flexibility for the round it is preparing for 2024. In 2021 Inbrain raised a total of 14.5 million euros from investors such as Sabadell Asabys, Alta Life Sciences, Vsquared, TruVenturo, CDTI and the ICF. At the European level, a year ago Inbrain was selected to receive funding of 17.5 million euros from the EIC Accelerator programme.

Inbrain is a spin-off of the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and the ICREA institute and is developing a neural graphene interface that can detect more biomarkers and do so more invasively than the current metal devices on the market for the treatment of central nervous system (CNS) diseases. Combined with the use of big data and artificial intelligence, its technology has the ability to read and modulate brain capacity and trigger responses in personalised therapies.

You may also be interested in:

• INBRAIN Neuroelectronics announces FDA breakthrough device designation for its graphene-based intelligent network modulation platform
• The European Commission supports INBRAIN Neuroelectronics as a strategic company for Europe’s Healthcare Innovation via the EIC Accelerator
• Inbrain and Merck collaborate on the next generation of bioelectronic therapies with graphene